The FDA has cleared LivaNova’s new nerve stimulation therapy system, the company announced.
The system consists of an implantable generator and the company’s programming system to treat drug-resistant epilepsy. The device is the smallest, lightest responsive epilepsy therapy to date.
The technology is proven to reduce number of seizures as well as lessen their duration and allow for faster recovery, according to the announcement. It is also the first device of its size to feature a pre-emptive “detect-and-respond” mode.